Elisabeth S.
- Country
- Germany
- Department
- Department of Internal Medicine I, Hematology, Oncology and Stem-Cell Transplantation
Research Overview
- Pilot-trial of methotrexate, tafasitamab (Minjuvi®), lenalidomide (Revlimid®) and rituximab in patients ineligible for HCT-ASCT with primary central nervous system lymphoma (PCNSL) -MTR²
- Phase III Randomized Trial of De-escalated MATRix Induction Therapy in Newly Diagnosed Primary CNS Lymphoma: Methotrexate, Cytarabine, Thiotepa, and Rituximab
- Phase III Randomized Trial of High-Dose Chemotherapy with Autologous Stem Cell Transplantation versus R-MP in Elderly Patients with Primary CNS Lymphoma
Data & Insights
Has run more than one trial at 35 of 74 partner sites.
Specializations
Central Nervous System Oncology
The investigator specializes in treating primary central nervous system lymphoma (PCNSL), with particular emphasis on diffuse large B-cell lymphoma affecting the brain and nervous system.
- CNS-specific lymphoma treatments
- Age-adapted therapeutic approaches
- Novel combination therapies
Their work focuses on optimizing treatment protocols for both elderly and standard-risk PCNSL patients.
Hematologic Therapeutics
The investigator develops innovative approaches in hematopoietic stem cell therapy and high-dose chemotherapy protocols for neurological malignancies.
- Autologous stem cell transplantation
- Rituximab-based therapies
- Combined modality treatments
Their research explores treatment optimization for patients with varying fitness levels and age groups.
Clinical Innovation
The investigator evaluates novel therapeutic combinations including targeted therapies and immunomodulatory approaches for CNS lymphomas.
- Treatment de-escalation strategies
- Quality of life assessment
- Alternative treatment protocols
Their work includes developing treatments for patients unable to receive intensive therapy regimens.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.